Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

n Therapeutics. "We are also very pleased with the safety profile demonstrated by Contrave thus far. We look forward to the results from the remaining Phase 3 trials which will further examine the efficacy, safety and tolerability of Contrave with less intensive behavior modification as well as in patients with Type 2 diabetes patients."

Patient enrollment has been completed in the three other Phase 3 trials. Orexigen expects to announce top-line results from these trials in mid-2009 and, pending additional positive results, submit a New Drug Application (NDA) with the FDA in late 2009.

Study Details and Results

The objective of this NB-302 trial was to determine the additional weight loss and health benefits of Contrave when added to an intensive diet and exercise program. The trial included the most intensive behavior modification regimen of the Phase 3 program for Contrave, which resulted, as expected, in a high degree of weight loss among placebo patients.

This 56-week, double-blind, placebo-controlled trial conducted at nine U.S. centers evaluated the efficacy and safety of Contrave (32mg naltrexone SR/360mg bupropion SR) compared to placebo in 793 obese patients who participated in an intense behavioral program consisting of counseling, diet and exercise. Patients enrolled in the trial were randomized on a 3 to 1 ratio between Contrave and placebo, and had a body mass index (BMI) of 30 to 45, or as low as 27 in the presence of cardiometabolic co-morbidities. Drug dosages were initially titrated over a four week period and then administered over 52 weeks of therapy at full dose. The co-primary endpoints were percent change in total body weight from baseline and proportion of patients who lost at least 5% of their baseline body weight.

    Efficacy results from this trial are summarized in the following table:

                          Intent-To-Treat*            
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... independent team of researchers from South ... (TB4) plays an important role in accelerating the ... an experimental mouse model, by promoting blood vessel ... dermal tissue.  The research found that the underlying ...
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... HONG KONG , May 4, 2015 ... or the "Company"), China,s leading ... cell processing and stem cell storage services, today announced ... Holdings Limited ("Golden Meditech"), a Hong Kong ... the Company, has entered into an agreement (the "Agreement") ...
(Date:5/4/2015)... , May 4, 2015   Tocagen Inc. ... interim data from Tocagen,s ongoing investigational studies were ... of the American Association of Neurological Surgeons (AANS)/Congress ... May 1-2, 2015, in Washington, D.C. ... held a meeting with FDA and continues to ...
Breaking Biology Technology:Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 2China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5
... Texas, June 22, 2011 Five exceptional oncology ... McKesson Specialty Care Solutions | US Oncology ... their patients. The Excellence in Oncology Nursing Award honors those ... who exemplify competency, courage and determination in providing the highest ...
... June 22, 2011 The Roche manuscript: "Immunoglobulin Domain ... Bispecific IgG Antibodies" has been published in the prestigious ... USA (PNAS). Corresponding authors are Wolfgang Schaefer, ... and Christian Klein, Head of Oncology Programs, Discovery Oncology ...
... June 22, 2011 VENENUM Biodesign, a drug discovery ... compound collection to identify potential therapeutic agents against its ... that it opened its new medicinal chemistry space at ... The facility comprises over 11,000 square feet of ...
Cached Biology Technology:McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 2McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 4Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... disabilities who are struggling to regain the use of ... engineers and students from Rochester Institute of Technology. ... the human body, to improve the performance of external ... disabilities, such as strokes or major spinal cord injuries, ...
... know all there is to know about Escherichia coli, ... has more than four thousand genes, and the functions ... Siegele, a biology professor at Texas A&M University whose ... , Harmless E. coli strains are normally found in ...
... Understanding, through its Institute for Arctic Studies, has ... Science Foundation through its Integrative Graduate Education and ... grant supports the development of an interdisciplinary doctoral ... a focus on rapid environmental change. "This grant ...
Cached Biology News:Robotics research: Enhancing the lives of people with disabilities 2GIANT-Coli: A novel method to quicken discovery of gene function 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 3
SHEEP ANTI FLECAINIDE...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
REGULATED IN DEVELOPMENT AND DNA DAMAGE RESPONSES 1,HIF-1 responsive RTP801...
Biology Products: